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Abstract Bordetella pertussis causes whooping cough or
pertussis, a highly contagious disease of the respiratory tract.
Despite high vaccination coverage, reported cases of pertussis
are rising worldwide and it has become clear that the current
vaccines must be improved. In addition to the well-known
protective role of antibodies and T cells during B. pertussis
infection, innate immune responses such as the complement
system play an essential role in B. pertussis killing. In order to
evade this complement activation and colonize the human
host, B. pertussis expresses several molecules that inhibit
complement activation. Interestingly, one of the known com-
plement evasion proteins, autotransporter Vag8, is highly
expressed in the recently emerged B. pertussis isolates. Here,
we describe the current knowledge on how B. pertussis evades
complement-mediated killing. In addition, we compare this to
complement evasion strategies used by other bacterial species.
Finally, we discuss the consequences of complement evasion
by B. pertussis on adaptive immunity and how identification
of the bacterial molecules and the mechanisms involved in
complement evasion might help improve pertussis vaccines.
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Introduction
The Gram-negative bacterium Bordetella pertussis causes per-
tussis or whooping cough, a highly contagious disease of the
respiratory tract of humans. B. pertussis is primarily transmit-
ted via direct contact or inhalation of airborne droplets ex-
pelled by infected individuals while coughing [1, 2]. Upon
infection, the bacteria attach to ciliated epithelium of the upper
respiratory tract where they multiply and express various vir-
ulence factors that favor colonization (Fig. 1) [2, 3]. These
virulence factors include, e.g., membrane-bound molecules
involved in adherence to the ciliated cells, secreted toxins,
and proteins that affect complement-mediated killing. Fre-
quently associated complications of pertussis are pneumonia,
otitis media, seizures, and (brain) hemorrhages [4]. Pertussis
was a leading cause of infant death before the introduction of
the whole-cell pertussis (wP) vaccines in the 1950s. Due to
side effects of the wP vaccine, acellular pertussis (aP) vaccines
were introduced in the late 1990s [5]. Despite high vac-
cination coverage, reported cases of pertussis have been
increasing over the past three decades [6, 7]. Possible
explanations for the re-emergence of pertussis are the
limited duration (waning) of aP vaccine-induced immunity
and pathogen adaptation. Other influencing factors may be
the increased awareness of disease and better diagnostic tools
for detection of pertussis [6, 8, 9].
To establish colonization and infection, pathogens have
developed various mechanisms to evade host immune re-
sponses including the complement system [10]. B. pertussis
is not an exception to this phenomenon. Here, we review what
is known about the interactions between B. pertussis and the
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complement system and how this pathogen evades
complement-mediated killing. In addition, we discuss how
identification of the molecules and the mechanisms involved
in complement evasion might help to improve the current
B. pertussis vaccines.
The role of complement in the host’s defense
against B. pertussis
The human complement system serves as the first line of de-
fense against microorganisms. The complement cascade can
Fig. 1 Interaction of B. pertussis with mucosal surfaces. The Gram-
negative bacterium B. pertussis interacts with ciliated epithelium in the
respiratory tract. Cilia are found in the trachea, bronchi, and bronchioles
and move continuously to keep the airway free of mucus-trapped micro-
organisms and dust. A number of B. pertussis proteins have been impli-
cated in adherence to host receptors, including pertactin (Prn), cell-bound
pertussis toxin (Ptx), filamentous hemagglutinin (FHA), fimbriae (Fim),
tracheal colonization factor A (TcfA), Bordetella resistance to killing
protein A (BrkA), the autotransporter Vag8, and other Bordetella
autotransporters (Bats). Ptx and adenylate cyclase toxin (ACT) are toxic
for host cells including phagocytes. Bordetella dermonecrotic toxin
(DNT) induces vasoconstriction in vitro. B. pertussis contains
lipooligosaccharide (LOS, or endotoxin) in its outer membrane. Type I,
III, and IV secretion systems are indicated in red, blue, and pink, respec-
tively. Ciliostasis is induced by tracheal cytotoxin (TCT) and may induce
bouts of intense coughing in whooping cough patients in order to remove
accumulated mucus
396 J Mol Med (2015) 93:395–402
be activated via three different pathways: the classical (CP),
lectin (LP), and/or the alternative pathway (AP) (Fig. 2). Ac-
tivation of any of the three pathways results in cleavage of C3
by C3 convertases which in turn leads to opsonization of bac-
teria with C3b. C3b deposition greatly enhances bacterial up-
take by phagocytic cells and can form a bridge between the
innate and adaptive immunity [11, 12]. In addition, C3b de-
position on the bacterial surface leads to formation of C5
convertases which cleave C5 into the strong chemo-
attractant C5a and C5b, which in turn initiates the formation
of the membrane attack complex (MAC) that can lyse Gram-
negative bacteria [13]. To prevent damage to human cells, the
complement system is strictly regulated and several comple-
ment regulatory proteins are described that can inhibit the CP,
LP, or AP [14]. Complement is not only present in the blood,
but also on healthy human mucosal surfaces of the upper
respiratory tract and the lungs. Moreover, almost all cells in
the human body can produce complement proteins (reviewed
in [15]). Therefore, complement can interfere with successful
colonization and persistence of bacteria in the upper respira-
tory tract and the lung [16–18].
In addition to direct killing of invading microbes, comple-
ment activation is also involved in other biological processes
of the human body [14] including the development and mod-
ulation of adaptive immune responses. Although it has long
been acknowledged that complement plays a role in regulating
B cell immunity [19], it has only recently become clear that
complement is also involved in inducing and directing T cell
responses [20]. This activation can occur through direct mod-
ulation of the Tcells themselves, or indirect activation through
alteration of mainly antigen presenting cells [21–23]. Further-
more, it has been shown that complement receptor-mediated
signaling can act in synergy with different innate receptors
such as Toll-like receptors, which promotes for example,
Fig. 2 Complement activation pathways. Complement activation is
mainly initiated via the CP and LP of complement. Initiation of
complement activation on the bacterial surface occurs via either C1q of
the CP or via mannose-binding lectin (MBL) or ficolins (FCNs) of the LP
and is indicated in red. Complement-fixing IgG, bound to the surface of
B. pertussis, activates the CP of complement. C1q, in complex with
proteases C1r and C1s binds to the bacterial surface and activates
complement C2 and C4. Similarly, MBL and/or FCNs are in complex
with serine protease MASP-1/-2/-3 (mannose-binding lectin-associated
serine protease-1/-2/-3) and binding the pathogen surface leads to
autoactivation of MASP-2, allowing cleavage of C2 and C4. C3
convertases can either cleave additional C3 into C3b, or bind C3b,
producing the C5 convertase (C4bC2aC3b). C5 convertases cleave C5
which in turn leads to the formation of the terminal pathway (indicated in
green) which produces the membrane attack complex (MAC). The
MAC is formed through the terminal assembly of complement
components C5b through C9 and results in cell lysis and death of
Gram-negative bacteria. The AP (indicated in yellow) involves the
continuous spontaneous hydrolysis of C3 into C3-HO, which binds to
factor B, producing Bb and Ba through the action of factor D. Properdin
binds and stabilizes the alternative C3 convertase C3bBb. The latter can
either cleave more C3 or forms the C5 convertase by incorporation of
another C3b molecule, producing the C5 convertase (C3bBbC3b).
The AP can be activated spontaneously and it can also amplify the
other pathways (as indicated with the orange arrows). In addition to
MAC formation, activation of the complement cascade results in
leukocyte chemotaxis and opsonization of the invading pathogen,
leading to enhanced phagocytosis
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Th17 differentiation which has been reported to be important
for protection against B. pertussis infections [24, 25]. Inhibi-
tion of complement activation by B. pertussis can therefore
also have consequences for the induction of the T cells re-
quired for protection against this pathogen.
Complement evasion strategies of B. pertussis
In order to infect and survive in the human host, pathogens
employ a broad range of strategies to escape recognition and
killing by various immune mechanisms, including the com-
plement system [10], and B. pertussis is no exception to this
phenomenon. Although research on the interaction with
B. pertussis and the innate immune system is limited, it is
known that in order to escape the complement system, this
bacterium expresses several complement evasion molecules.
Unl ike Bordete l la parapertuss is and Bordetel la
bronchiseptica, which can cause infectious bronchitis in
humans [7], B. pertussis does not expresses lipopolysaccha-
ride containing O-antigen. Murine infection models show that
lipopolysaccharide containing O-antigen facilitates coloniza-
tion of the respiratory tract of mice and also plays an important
role in the protection against complement-mediated killing
since it prevents C3b deposition on the bacteria surface [26,
27]. In addition to O-antigen, other surface polysaccharides
have also been shown to provide complement resistance [28,
29]. Like other bacterial pathogens, B. pertussis expresses a
polysaccharide (Bps) which belongs to a large family of β-(1-
6)-linked polymeric-N-acetylglucosamine (GlcNAc) polysac-
charides. Bps polysaccharide was shown to be essential for
early colonization of the respiratory tract of mice by
B. pertussis [30, 31]. Recent studies show that Bps mutant
strains are more sensitive to complement-mediated killing
compared to the B. pertussiswild-type strain [32, 31]. Asmice
are not the natural reservoir ofB. pertussis and its pathology of
infection is different from humans, further studies are needed
to establish the effect of surface polysaccharides during infec-
tions in humans. In addition to surface polysaccharides,
B. pertussis expresses several other proteins involved in com-
plement evasion (Fig. 3) which are described in detail below.
The 103-kDa autotransporter, Bordetella resistance to kill-
ing A (BrkA) protein of B. pertussis promotes attachment to
human cells and has also been shown to be involved in com-
plement evasion [33] (Fig. 3a). Studies using a BrkA mutant
and a BrkA overexpressing B. pertussis strain demonstrated
that BrkA reduces C4 and C3 deposition on the bacterial sur-
face and subsequently, the formation of the MAC complex
Fig. 3 Complement resistance mechanisms of B. pertussis. B. pertussis
has evolved several strategies to evade complement activation. a BrkA,
an autotransporter of B. pertussis, has been shown to be involved in
complement evasion. The exact mechanism of how BrkA inhibits
complement activation remains unknown. b B. pertussis binds C1-inh
to the bacterial surface which increased resistance to complement-
mediated killing. The Vag8 protein of B. pertussis was identified as the
C1-inh binding factor. c B. pertussis binds C4BP via its surface protein
FHA and possibly via one or more other receptors. Strains deficient in
FHA were still able to bind C4BP, although strongly reduced. d
B. pertussis isolates recruit host complement regulators that are part of
the fH family such as complement CFH, factor H-like 1 (CFHL), and
factor H-related (CFHR) proteins by expressing one or more receptors
that have not yet been identified
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[34]. Since C1q deposition was not altered by BrkA, the au-
thors conclude that BrkA either promotes degradation of C4b
on the bacterial surface or inhibits C4 activation [34]. The
authors did not investigate a potential direct effect of BrkA
on C1, C2, and/or C4. Direct binding of BrkA to those pro-
teins could result in conformational changes of these proteins,
thereby preventing their activation. Another possibility is in-
activation of C1, C2, and/or C4 by BrkAvia proteolytic cleav-
age. Furthermore, all studies were performed with whole bac-
teria rather than recombinant BrkA so it cannot be excluded
that BrkA is indirectly involved in complement inhibition
rather than directly. Therefore, the precise mechanism by
which BrkA inhibits complement activation remains to be
fully elucidated. Recent studies also identified another
autotransporter protein, Bordetella autotransporter protein-C
(BapC) that is involved in serum resistance. Although it was
shown that a BapC mutant of B. pertussis is more susceptible
to serum killing, the mechanism of action remains unidenti-
fied [35].
A frequently used mechanism by pathogens to evade
complement-mediated killing is the acquisition of host com-
plement regulators on their surfaces [10]. The host comple-
ment regulator C1 esterase inhibitor (C1-inh) belongs to the
superfamily of serine protease inhibitors. C1-inh binds irre-
versibly to and inactivates both C1r and C1s proteases of the
CP and mannan-binding lectin-associated serine protease
(MASP)-1 and MASP-2 of the LP [36]. B. pertussis, but not
the related B. bronchiseptica, B. parapertussis, Bordetella
holmesii, or Bordetella avium, recruits C1-inh to its bacterial
surface to inhibit complement activity [37]. The binding of
C1-inh to the bacterial surface is dependent on the expression
of genes that are under control of the Bordetella master viru-
lence regulatory locus (bvgAS) [37]. The BvgAS proteins
form part of a two-component sensory transduction system
which is regulated by environmental signals. Growth in the
presence of sulfate, nicotinic acid, or low temperature results
in lack of expression of the bvg-activated genes and results in
an avirulent phenotype of this bacterium [38]. Using different
growth conditions, the authors showed that C1-inh binding
occurred only during the virulent phase. Recently, the passen-
ger domain of the autotransporter Vag8 was identified as the
C1-inh binding factor of B. pertussis. Importantly, Vag8 ex-
pression correlates with serum resistance [39] (Fig. 3b). Inter-
estingly, the B. pertussis ptxP3 (or P3) lineage which has
recently expanded globally, produces higher amounts of
Vag8 than the strains it replaced [40]. In addition to
B. pertussis, only one other pathogenic bacterium was shown
to bind C1-inh. Escherichia coli strain 0157:H7 can bind C1-
inh to its surface via the metalloprotease StcE, to evade the
complement system [41, 42].
The host complement regulator C4b-binding protein
(C4BP) also inhibits complement activation via the CP and
LP. C4BP is a spider-like molecule of 570 kDa, composed of
seven identical α-chains and one β-chain held together by di-
sulfide bridges. Both chains are composed of complement
control protein domains (CCPs). C4BP binds to C4b, thereby
dissociating the CP/LP C3 convertase C4b2a and it acts as a
cofactor for the plasma protease factor I in the proteolytic
degradation of C4b [10]. B. pertussis binds C4BP via its sur-
face protein filamentous hemagglutinin (FHA) [43] (Fig. 3c).
Although C4BP binding to B. pertussis occurs under physio-
logical conditions and C4BP retains its complement regulato-
ry activity when surface-bound [44], protection from
complement-mediated lysis has not been proven. B. pertussis
mutants that do not express FHA have a similar sensitivity
toward complement compared to the wild-type strain [45].
Studies using C4BP mutants show that B. pertussis binds
C4BP at the CCP1-2 domain interface of the α-chain. Amino
acids R64 and R66 of C4BP are the major players in the
binding site. Moreover, studies with mAb directed towards
the C4BP α-chain indicate that B. pertussis binds C4BP at a
site similar to the C4b-binding site [44]. Although strongly
reduced, fhamutants were still able to bind C4BP. bvgmutants
failed to bind C4BP [43] indicating that besides FHA, one or
more BvgAS-regulated proteins contribute to the binding of
C4BP (Fig. 2b). Binding of C4BP to bacterial pathogens is a
common phenomenon. Neisseria meningitidis binds C4BP
via its type IV Pili [46], group A streptococcus binds C4BP
via the M-protein family member Sir and Arp [47, 48] and
also E. coli strain K1 binds C4BP via outer membrane protein
A [49].
Finally, B. pertussis and B. parapertussis are both capable
of binding host-derived negative complement regulator fH
family proteins including factor H-like (FHL)-1 and factor
H-related (FHR)-1. Binding of fH family proteins by patho-
gens contributes to their survival in human serum [50]
(Fig. 3d). FH, the main negative regulator of the AP, consists
of 20 short consensus repeat (SCR) domains and recent stud-
ies show that B. pertussis binds fH via SCR20 and SCR5-7
[51, 50]. FH binding by other pathogenic bacteria such as
Pseudomonas aeruginosa,Haemophilus influenza, and Strep-
tococcus pneumoniae occurs via SCR19-20 through a com-
mon site in SCR20 named the Bcommon microbial binding
site.^ This binding site allows the formation of a tripartite
microbial protein: fH:C3b complex which enhances fH-
mediated inactivation of C3b. A similar mechanism of com-
plement evasion has not yet been shown for B. pertussis [51]
since the fH binding protein(s) of B. pertussis remains uniden-
tified. Ptx could be involved in fH binding since an isogenic
strain of Tohama I, lacking Ptx, is more sensitive to serum
killing via the AP than the parental strain [50]. Taken together,
B. pertussis produces various complement evasion molecules
to successfully colonize and persist in the human host. We
hypothesize that B. pertussis expresses more, yet unidentified,
molecules for regulating complement activation since other
well studied bacteria have proven to express at least a dozen.
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Complement evasion molecules and vaccine development
The recent increase in pertussis cases worldwide has made it
clear that further research on the pathogenesis and immunity of
B. pertussis is required for the development of a new generation
of vaccines. Besides humans, no other reservoirs forB. pertussis
have been described. Therefore, strain adaptation is driven by
the human immune system only and waning immunity may
accelerate this process by allowing a high circulation rate of
the pathogen [52]. Next-generationB. pertussis vaccines should
include antigen preparations that induce long-lasting immunity
and strengthens the innate immune system. Strengthening in-
nate immune responses will result in elimination of B. pertussis
immediately after exposure to this bacterium, preventing trans-
mission and thereby, opportunities for strain adaptation.
New-generation vaccines against a number of pathogens are
currently converging on the use of complement evasion mole-
cules as vaccine targets. The best example is factor H binding
protein (fHbp) of N. meningitidis, which is the leading antigen
in vaccine development against N. meningitidis serogroup B
[53]. fHbp binds to fH providing an important mechanism for
immune evasion by inhibition of the complement system [54,
55]. Next to the vaccine againstN. meningitidis, other vaccines
containing complement evasion molecules are also investigat-
ed [56, 57]. BibA is a virulent factor from group B
Streptococcus that is able to bind to C4BP and promotes ad-
hesion of group B streptococcus to human epithelial cells [58].
Recent studies also indicate pneumococcal proteins PspA and
PspC as potential vaccine candidates. PspA and PspC are im-
portant virulence factors expressed by almost all pneumococ-
cal strains. Both proteins are known as complement evasion
molecules. PspA interferes with complement deposition on the
bacterial surface and PspC binds to fH [59, 60].
The aP vaccine for B. pertussis consists of Ptx, Fim, FHA,
and Prn (depending on which country). As described above in
detail, FHA is a known C4BP-binding molecule [43, 44].
Recent studies show that vaccination with Vag8, the C1-inh
binding protein of B. pertussis, results in a protective immune
response against B. pertussis in mice [52]. All these data to-
gether underline the promising perspective of using comple-
ment modulating proteins in new vaccines.
Studies to identify additional molecules involved in com-
plement evasion by B. pertussis are needed to develop new
and improved vaccines against B. pertussis. Vaccines contain-
ing B. pertussis complement evasion molecules will prevent
complement escape and complement downregulation. Effec-
tive activation of the complement system is important since
the function of the complement system goes beyond
protecting the host from infection by immediate elimination
of pathogens; it is also involved in modulation of adaptive
immune responses [14]. Altogether, it is of crucial importance
to unravel the complement evasion strategies of B. pertussis in
order to improve the existing vaccines against pertussis.
Concluding remarks
Despite high vaccination coverage, reported cases of pertussis
are rising which clearly indicates the urgency for a more ef-
fective vaccine [9]. The role of the complement system in
protection against B. pertussis has only recently become ap-
parent [25, 61], and research on complement evasion by
B. pertussis is limited. We propose that improved pertussis
vaccines should contain antigen preparations that, in addition
to inducing long-lasting immunity, can prevent suppression of
the innate immune response by B. pertussis. One of the pos-
sibilities is inclusion of complement evasion molecules in cur-
rent aP vaccines. Neutralizing complement evasion molecules
would allow more efficient activation of the complement sys-
tem upon exposure to B. pertussis, which will result in faster
eradication of the bacteria and potentially leads to a better
activation of the adaptive immunity. In conclusion, comple-
ment evasion molecules are undoubtedly promising vaccine
candidates.
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